India's 4th largest pharma company has given breakout..Hello Guy's i hope you all will be doing good in your life and your trading as well. I have brought another stock which has given breakout of small rectangle pattern on daily timeframe. Company has good management with proven profits making record, it is 4th Consumer Healthcare brands Market ranked
Next report date
Report period
Q4 2023
EPS estimate
9.62INR
Revenue estimate
24.03 BINR
43.10INR
12.82 BINR
87.43 BINR
64.42 M
About MANKIND PHARMA LTD
Sector
CEO
Sheetal Arora
Headquarters
New Delhi
Website
Employees (FY)
18.47 K
Founded
1986
ISIN
INE634S01028
FIGI
BBG01G9WXGC8
Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. It offers products under the brands of Nurokind, Telmikind, Manforce, Unwanted, Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Prega News, Dydroboon, Cefakind, Monticope, and Caldikind. The company was founded by Ramesh Chand Juneja in 1986 and is headquartered in New Delhi, India.
MANKIND#MANKIND gave a good breakout from the range on a good volume. I am expecting the stock to reach a new high.
Momentum InvestingRule 1 : Respect Target & Stoploss.
Rule 2 : Hold the Trade until the Rule 1 is not met.
Rule 3 : SL on Day Close Basis
Rule 4 : On result day trail your SL at 15Min Time Frame
Mankind pharma reversal.EMA 9/21 cross on daily chart.
RSI above 50.
MACD Crossover above zero line with green candle.
I wish it will give good returns Technically best stock from my side it is looking good for going outside it has given in 8 month 76% return fundamently also good and companies doing good
this stock can go a long way upFib Analysis- the retracement to 38.2% from a higher zone is an indication of tremendous strength. In my view this is just the start of a big rally in this newly listed counter
Good breakout on Weekly / Daily Timeframe - MANKINDCheckout an amazing breakout happened in the stock in Weekly timeframe, macroscopically seen in Daily timeframe. Having a great favour that the stock might be bullish expecting a staggering returns of minimum 25% TGT. IMPORTANT BREAKOUT LEVELS ARE ALWAYS RESPEECTED!
Super Setup 📌Super Setup
✅Keep in Your watchlist
MANKIND
+ Setting up nicely
+ Volume Dryup
+ Selling pressure being absorbed
Is Mankind pharma ready for Wave 2 rally?Posted decent Quarterly numbers, Revenue up 11% at Rs 2708.1 Cr. EBIDTA up 15% Rs. 682.7 Cr.
Maintaining healthy margin of 25.2%.
The stock has been sideways after wave 1 rally post its listing. The stock did a Fib 0.38 retracement and holding on it Symmetrical triangle formation and breakout above
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MANKIND is 2364.40 INR — it has decreased by 0.53% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange MANKIND PHARMA LTD stocks are traded under the ticker MANKIND.
MANKIND PHARMA LTD is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
MANKIND stock is 2.72% volatile and has beta coefficient of 0.44. Check out the list of the most volatile stocks — is MANKIND PHARMA LTD there?
MANKIND earnings for the last quarter are 12.50 INR per share, whereas the estimation was 12.75 INR resulting in a −1.96% surprise. The estimated earnings for the next quarter are 9.87 INR per share. See more details about MANKIND PHARMA LTD earnings.
MANKIND PHARMA LTD revenue for the last quarter amounts to 27.08 B INR despite the estimated figure of 27.08 B INR. In the next quarter revenue is expected to reach 23.58 B INR.
Yes, you can track MANKIND PHARMA LTD financials in yearly and quarterly reports right on TradingView.
MANKIND stock has fallen by 0.23% compared to the previous week, the month change is a 0.61% rise, over the last year MANKIND PHARMA LTD has showed a 81.88% increase.
MANKIND net income for the last quarter is 4.54 B INR, while the quarter before that showed 5.01 B INR of net income which accounts for −9.43% change. Track more MANKIND PHARMA LTD financial stats to get the full picture.
Today MANKIND PHARMA LTD has the market capitalization of 954.92 B, it has increased by 2.44% over the last week.
No, MANKIND doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MANKIND shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MANKIND PHARMA LTD stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 30, 2024, the company has 18.47 K employees. See our rating of the largest employees — is MANKIND PHARMA LTD on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MANKIND PHARMA LTD technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MANKIND PHARMA LTD stock shows the neutral signal. See more of MANKIND PHARMA LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MANKIND PHARMA LTD future price: according to them, MANKIND price has a max estimate of 2520.00 INR and a min estimate of 1750.00 INR. Read a more detailed MANKIND PHARMA LTD forecast: see what analysts think of MANKIND PHARMA LTD and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MANKIND PHARMA LTD EBITDA is 23.61 B INR, and current EBITDA margin is 22.23%. See more stats in MANKIND PHARMA LTD financial statements.